J S McCombs

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years
    J S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 3:222-31. 2000
  2. ncbi request reprint Access to drug therapy and substitution between alternative antidepressants following an expansion of the California Medicaid formulary
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, USC School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    Health Policy 65:301-11. 2003
  3. ncbi request reprint Use patterns for antipsychotic medications in medicaid patients with schizophrenia
    J S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles 90033, USA
    J Clin Psychiatry 60:5-11; discussion 12-3. 1999
  4. ncbi request reprint A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA
    Clin Ther 24:1939-59; discussion 1938. 2002
  5. ncbi request reprint Antipsychotic drug use patterns and the cost of treating schizophrenia
    J S McCombs
    Department of Pharmaceutical Economics and Policy, Univeristy of Southern California, 1540 East Alcazar Street, Los Angeles, USA
    Psychiatr Serv 51:525-7. 2000
  6. ncbi request reprint Use of conventional antipsychotics and the cost of treating schizophrenia
    R R Lyu
    School of Pharmacy, University of Southern California, USA
    Health Care Financ Rev 23:83-99. 2001
  7. ncbi request reprint Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program
    Jinmei Li
    Department of Pharmaceutical Economics and Policy, University of Southern California School of Pharmacy, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    J Affect Disord 71:131-9. 2002
  8. doi request reprint The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia
    Lei Chen
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 11:34-43. 2008
  9. ncbi request reprint The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90089 9004, USA
    J Affect Disord 97:171-9. 2007
  10. doi request reprint Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
    Jeonghoon Ahn
    University of Southern California, Los Angeles, CA, USA
    Value Health 11:48-56. 2008

Collaborators

Detail Information

Publications20

  1. ncbi request reprint The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years
    J S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 3:222-31. 2000
    ..To evaluate the association between drug therapy patterns achieved with conventional antipsychotics and direct healthcare costs over 2 years...
  2. ncbi request reprint Access to drug therapy and substitution between alternative antidepressants following an expansion of the California Medicaid formulary
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, USC School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    Health Policy 65:301-11. 2003
    ..However, while some expansion in overall antidepressant use may have been desired, the clinical validity of this expansion cannot be determined based on the results presented here...
  3. ncbi request reprint Use patterns for antipsychotic medications in medicaid patients with schizophrenia
    J S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles 90033, USA
    J Clin Psychiatry 60:5-11; discussion 12-3. 1999
    ..We investigated the use patterns for antipsychotic medications generated by Medicaid patients with schizophrenia...
  4. ncbi request reprint A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA
    Clin Ther 24:1939-59; discussion 1938. 2002
    ..The California Medicaid (Medi-Cal) program removed prior authorization restrictions for 2 selective serotonin reuptake inhibitors (SSRIs), fluoxetine and paroxetine, in May 1996...
  5. ncbi request reprint Antipsychotic drug use patterns and the cost of treating schizophrenia
    J S McCombs
    Department of Pharmaceutical Economics and Policy, Univeristy of Southern California, 1540 East Alcazar Street, Los Angeles, USA
    Psychiatr Serv 51:525-7. 2000
    ..Completing one year of uninterrupted drug therapy was correlated with higher nursing home costs. Delayed drug treatment and changes in therapy increased the cost by $9,418 and $9,719, respectively...
  6. ncbi request reprint Use of conventional antipsychotics and the cost of treating schizophrenia
    R R Lyu
    School of Pharmacy, University of Southern California, USA
    Health Care Financ Rev 23:83-99. 2001
    ..0001); 41 percent of treated patients changed therapy with similar results (+$4,067, p < .0001). Only 20 percent of patients were compliant with drug therapy but this had no significant impact on total treatment costs...
  7. ncbi request reprint Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program
    Jinmei Li
    Department of Pharmaceutical Economics and Policy, University of Southern California School of Pharmacy, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    J Affect Disord 71:131-9. 2002
    ..The objective of this study was to document the use patterns with mood stabilizers achieved by patients with bipolar disorder and to estimate the direct health care costs associated with sub-optimal drug therapy...
  8. doi request reprint The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia
    Lei Chen
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 11:34-43. 2008
    ..Using data in real-world clinical practice, this study aims to compare the health-care use patterns of patients with schizophrenia who use oral antipsychotics...
  9. ncbi request reprint The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA 90089 9004, USA
    J Affect Disord 97:171-9. 2007
    ..The cost of unrecognized bipolar disorders over time is unknown...
  10. doi request reprint Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
    Jeonghoon Ahn
    University of Southern California, Los Angeles, CA, USA
    Value Health 11:48-56. 2008
    ..This study identifies latent classes defined by varying degrees of adherence to antipsychotic drug therapy and examines the sociodemographic, clinical, and resource utilization correlates associated with membership in each adherence class...
  11. pmc A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study
    Danielle C Colayco
    University of Southern California School of Pharmacy, Department of Pharmaceutical Economics and Policy, Los Angeles, California, USA
    Diabetes Care 34:77-83. 2011
    ..The role of aggressive glycemic control in preventing cardiovascular events is unclear. A nested case-control study design was used to evaluate the association between average A1C and cardiovascular outcomes...
  12. ncbi request reprint Open access to innovative drugs: treatment substitutions or treatment expansion?
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy School of Pharmacy, University of Southern California, USA
    Health Care Financ Rev 25:35-53. 2004
    ..Program administrators must use caution when evaluating the impact of unrestricted access on drug therapy outcomes and treatment costs given the changes in the characteristics of patients seeking treatment...
  13. ncbi request reprint Compliance with drug therapies for the treatment and prevention of osteoporosis
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Maturitas 48:271-87. 2004
    ..This study used paid claims data from real-world treatment settings to investigate the impact of hormone replacement therapy (HRT), bisphosphonate and raloxifene on patients with a recorded diagnosis of osteoporosis...
  14. ncbi request reprint Medication use in residential care facilities for the elderly
    B R Williams
    Clinical Pharmacy and Clinical Gerontology, School of Pharmacy, University of Southern California, and Ethel Percy Andrus Gerontology Center, Los Angeles 90033, USA
    Ann Pharmacother 33:149-55. 1999
    ..To describe medication use by residents of residential care facilities for the elderly (RCFEs)...
  15. doi request reprint Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results
    Lei Chen
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 11:487-96. 2008
    ..This study compares the TTAD achieved when using alternative antipsychotics to treat patients with schizophrenia in real-world practice settings...
  16. ncbi request reprint Pharmacoeconomics: what is it and where is it going?
    J S McCombs
    University of Southern California School of Pharmacy, Pharmaceutical Economics and Policy, Los Angeles 90033, USA
    Am J Hypertens 11:112S-119S; discussion 135S-137S. 1998
    ....
  17. ncbi request reprint The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Affect Disord 82:373-83. 2004
    ..This study compares hospital use, suicide risk and health care costs of antidepressant patients with recognized bipolar disorders (recognized-BP) and unrecognized bipolar disorders (unrecognized-BP) with non-bipolar (non-BP) patients...
  18. ncbi request reprint Effects of ambulatory-care pharmacist consultation on mortality and hospitalization
    Yong Yuan
    Global Epidemiology Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
    Am J Manag Care 9:45-56. 2003
    ..To determine the effect of 3 alternative models of ambulatory-care pharmacist consultation on patient survival and hospitalization...
  19. ncbi request reprint Defining and measuring clinical effectiveness in the treatment of schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
    Psychiatr Serv 56:273-82. 2005
    ..This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives...
  20. ncbi request reprint Can pharmacy data improve prediction of hospital outcomes? Comparisons with a diagnosis-based comorbidity measure
    Joseph P Parker
    Health Care Quality and Analysis Division, California Office of Statewide Health Planning and Development, Sacramento 95814, USA
    Med Care 41:407-19. 2003
    ....